[Current Condition and Issues of Clinical Biobanks in Japan -From the Point of View of Laboratory Medicine-].

Kazuyuki Matsushita
{"title":"[Current Condition and Issues of Clinical Biobanks in Japan -From the Point of View of Laboratory Medicine-].","authors":"Kazuyuki Matsushita","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>The final goal or aim of clinical biobanks is to share sample data and feed back their results to the public. For this purpose, it is essential to establish sustainable systems to share clinical samples among researchers of academic institutes as well as commercial companies. So far, clinical biobanks have been considered an infrastructure that is advantageous or valuable for checking developing reagents, searching for companion biomarkers for diseases, cohort research, and constructing medical big data. However, easy-to-approach systems to access clinical samples between academia and commercial companies have yet to be established in Japan. The major reasons are ethical, legal, and social issues (ELSI), the lack of simple procedures to evaluate stored samples, and the financial burden among participants. Additionally, the cultivation/training of human resources in related fields is also required. Needless to say, laboratory medicine is expected to play responsible roles in this field. Recently, next-generation DNA sequencers (NGS) have begun to be used in clinics, called clinical sequences, based on the samples of clinical biobanks. Clinical biobanks that preserve standardized and/or high-quality clinical samples are required. Further, to accomplish \"precision medicine\" or \"individualized medicine\", NGS/clinical sequence/genetic testing by high-quality DNA samples is required. The authors discussed the problem lists and ELSI to overcome these situations in order to establish commercially available clinical biobank networks in Japan. Since so-called \"medical big-data\" based on personal data will lead to the development of future medicine, the rules or consensus in clinical biobanks for treating and/or sharing personal clinical data is also discussed. Furthermore, the concepts of clinical biobanks and clinical sequencing are considered regarding their ability to accelerate clinical biomarker research in this manuscript.</p>","PeriodicalId":21457,"journal":{"name":"Rinsho byori. The Japanese journal of clinical pathology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2017-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Rinsho byori. The Japanese journal of clinical pathology","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The final goal or aim of clinical biobanks is to share sample data and feed back their results to the public. For this purpose, it is essential to establish sustainable systems to share clinical samples among researchers of academic institutes as well as commercial companies. So far, clinical biobanks have been considered an infrastructure that is advantageous or valuable for checking developing reagents, searching for companion biomarkers for diseases, cohort research, and constructing medical big data. However, easy-to-approach systems to access clinical samples between academia and commercial companies have yet to be established in Japan. The major reasons are ethical, legal, and social issues (ELSI), the lack of simple procedures to evaluate stored samples, and the financial burden among participants. Additionally, the cultivation/training of human resources in related fields is also required. Needless to say, laboratory medicine is expected to play responsible roles in this field. Recently, next-generation DNA sequencers (NGS) have begun to be used in clinics, called clinical sequences, based on the samples of clinical biobanks. Clinical biobanks that preserve standardized and/or high-quality clinical samples are required. Further, to accomplish "precision medicine" or "individualized medicine", NGS/clinical sequence/genetic testing by high-quality DNA samples is required. The authors discussed the problem lists and ELSI to overcome these situations in order to establish commercially available clinical biobank networks in Japan. Since so-called "medical big-data" based on personal data will lead to the development of future medicine, the rules or consensus in clinical biobanks for treating and/or sharing personal clinical data is also discussed. Furthermore, the concepts of clinical biobanks and clinical sequencing are considered regarding their ability to accelerate clinical biomarker research in this manuscript.

[日本临床生物库的现状与问题——从检验医学的角度看]。
临床生物银行的最终目标是共享样本数据并将结果反馈给公众。为此,在学术机构和商业公司的研究人员之间建立可持续的临床样本共享系统至关重要。迄今为止,临床生物库一直被认为是一种有利或有价值的基础设施,可用于检查开发试剂、寻找疾病的伴随生物标志物、队列研究和构建医疗大数据。然而,在日本尚未建立学术界和商业公司之间获取临床样本的易于接近的系统。主要原因是伦理、法律和社会问题(ELSI),缺乏简单的程序来评估储存的样品,以及参与者的经济负担。此外,还需要培养/培训相关领域的人力资源。毋庸置疑,检验医学将在这一领域发挥重要作用。最近,以临床生物银行样本为基础的下一代DNA测序仪(NGS)被称为临床序列,开始在临床中应用。需要保存标准化和/或高质量临床样本的临床生物库。此外,要实现“精准医疗”或“个体化医疗”,需要通过高质量的DNA样本进行NGS/临床序列/基因检测。为了在日本建立商业化的临床生物库网络,作者讨论了问题清单和ELSI以克服这些情况。由于基于个人数据的所谓“医疗大数据”将引领未来医学的发展,因此本文也讨论了临床生物银行处理和/或共享个人临床数据的规则或共识。此外,临床生物银行和临床测序的概念考虑到它们加速临床生物标志物研究的能力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信